{
    "clinical_study": {
        "@rank": "121011", 
        "arm_group": {
            "arm_group_label": "treatment", 
            "arm_group_type": "Experimental", 
            "description": "HD  IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion; SABR dose varying from 8Gy-20Gy in 1-3 fractions."
        }, 
        "brief_summary": {
            "textblock": "In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the\n      stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites\n      of bulky progressive disease, but also to provide antigen presentation and immune\n      stimulation which is expected to act synergistically when immediately followed by the\n      non-specific immune stimulation provided by treatment with HD IL-2 and thereby increase the\n      response rate and complete response for metastatic clear cell renal cell cancer patients.\n      Both HD IL-2 and SABR are FDA approved therapeutic cancer treatment"
        }, 
        "brief_title": "High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Clear Cell Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Biopsy-proven metastatic clear cell RCC.\n\n          2. Radiographic evidence of metastatic disease. 2.1  Patients with any number of\n             metastatic site are allowed to enroll. However, only up to six sites will be selected\n             for SBRT treatment, at the discretion of the treating radiation oncologist.\n\n          3. Patient must have \u22651 lesion of size >1.5cm.\n\n          4. Previous treatment with surgery, radiation, chemotherapy, immunotherapy or any\n             targeted agents are allowed 28 days before the start of HD IL-2\n\n          5. Age \u2265 18 years.\n\n          6. Performance status ECOG 0, 1.\n\n          7. Patient must be eligible for HD IL-2 treatment\n\n          8. Patient must be eligible for SABR to one or more extra cranial sites.\n\n          9. Adequate organ and marrow function as defined below:\n\n               -  leukocytes   \u2265 3,000/mcL\n\n               -  absolute neutrophil count \u2265 1,500/mcL\n\n               -  platelets   \u2265 50,000/mcl\n\n               -  total bilirubin  \u2264 2mg/dL\n\n               -  AST(SGOT)/ALT(SPGT) \u2264 2.5 X institutional upper limit of normal\n\n         10. Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry, for\n             the duration of study participation. Should a woman become pregnant or suspect she is\n             pregnant while participating in this study, she should inform her treating physician\n             immediately.\n\n             10.1 A female of child-bearing potential is any woman (regardless of sexual\n             orientation, having undergone a tubal ligation, or remaining celibate by choice) who\n             meets the following criteria:\n\n               -  Has not undergone a hysterectomy or bilateral oophorectomy; or\n\n               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,\n                  has had menses at any time in the preceding 12 consecutive months).\n\n         11. Ability to understand and the willingness to sign a written informed consent\n\n         12. Adequate Renal function with Cr \u2264 1.6 mg/dL.\n\n         13. Adequate cardiac function (adequate perfusion; no ischemia) on thallium (or Tc)\n             stress test\n\n         14. Adequate pulmonary function on PFT (FEV1 >65%; DLCO>60%).\n\n        Exclusion Criteria:\n\n          1. Subjects who have had chemotherapy or radiotherapy within 4 weeks prior to entering\n             the study\n\n          2. History of HIV, Hepatitis B, Hepatitis C and HTLV serology\n\n          3. Subjects may not be receiving any other investigational  or standard antineoplastic\n             agents.\n\n          4. Subjects with known brain metastases should be excluded from this clinical trial\n             because of their poor prognosis\n\n          5. Subjects with life expectancy < 6 months.\n\n          6. History of allergic reactions to recombinant IL-2\n\n          7. Uncontrolled recurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia,.\n\n          8. Psychiatric illness/social situations that would limit compliance with study\n             requirements.\n\n          9. Subjects must not be pregnant or nursing due to the potential for congenital\n             abnormalities and the potential of this regimen to harm nursing infants.\n\n         10. Systemic or topical steroid use or other immunosuppressive therapy  within the past\n             28 days\n\n         11. Subjects required to take corticosteroids or other immunosuppressive therapy such as\n             those with organ allograft"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896271", 
            "org_study_id": "STU 012013-041"
        }, 
        "intervention": [
            {
                "arm_group_label": "treatment", 
                "description": "HD  IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion", 
                "intervention_name": "IL-2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "treatment", 
                "description": "SABR dose varying from 8Gy-20Gy in 1-3 fractions", 
                "intervention_name": "Stereotactic Ablative Body Radiation Therapy", 
                "intervention_type": "Radiation", 
                "other_name": "SABR, SBRT"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interleukin-2"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "kidney cancer", 
            "metastatic cancer"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390"
                }, 
                "name": "University of Texas Southwestern Medical Center"
            }, 
            "investigator": {
                "last_name": "Raquibul Hannan, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC)", 
        "overall_contact": {
            "email": "raquibul.hannan@utsouthwestern.edu", 
            "last_name": "Raquibul Hannan, MD, PhD", 
            "phone": "214-645-8525"
        }, 
        "overall_official": {
            "affiliation": "University of Texas Southwestern Medical Center", 
            "last_name": "Raquibul Hannan, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the response rate (RR) in patients with mRCC after treatment with HD IL-2 immediately following SABR to multiple metastatic sites.  RR has been highly correlated (p<0.0001) to overall survival.  RECIST 1.1 criteria will be used to measure RR and it will consist of complete response (CR) and partial response (PR)", 
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896271"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the overall survival (OS), which is defined as the time between date of registration and the date of death due to any cause. In analyzing the OS, it is important to take into account the MSKCC prognostic criteria defined by Motzer et. al. mRCC patients and compare the outcome in the appropriate risk categories", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "To evaluate progression free survival (PFS), which is defined as the time between date of registration and the first date of documented disease progression or date of death due to any cause.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "To evaluate time to progression (TTP), which is defined as time between date of registration and date of documented progression", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "To evaluate median response duration, which is defined as the time between the date a response (CR or PR) was first seen until date of progression", 
                "measure": "Median response duration", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "To evaluate the local control rate of irradiated lesions", 
                "measure": "Local control rate", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "To measure treatment-related tumor-specific immune response", 
                "measure": "Tumor-specific immune response", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "To evaluate the tolerability and toxicity of this regiment as measured according to CTCAE v4.0.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "To measure the improvement in health-related quality of life (HRQoL)", 
                "measure": "Health-related quality of life (HRQoL).", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }
        ], 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Prometheus Therapeutics and Diagnostics", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}